Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Middleton, M R Pwint, T Swaisland, H Carmichael, J Goodege-Kunwar, P Ranson, Malcolm R
Middleton, M R
Pwint, T
Swaisland, H
Carmichael, J
Goodege-Kunwar, P
Ranson, Malcolm R
Citations
Altmetric:
Abstract
Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of care with chemotherapy in various tumours. This phase I study established the safety, tolerability and clinical pharmacokinetics of olaparib alone and in combination with bevacizumab.
Description
Date
2012-01-31
Publisher
Collections
Keywords
Type
Article
Citation
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. 2012, 106 (3):468-74 Br J Cancer